Flputnam Investment Management Co. bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report) during the second quarter, HoldingsChannel reports. The firm bought 52,975 shares of the company’s stock, valued at approximately $1,177,000.
A number of other large investors also recently bought and sold shares of DYN. Fisher Asset Management LLC bought a new position in Dyne Therapeutics during the fourth quarter worth $4,891,000. Cibc World Market Inc. bought a new stake in Dyne Therapeutics during the fourth quarter valued at $1,345,000. Clearbridge Investments LLC acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth $7,976,000. Frazier Life Sciences Management L.P. boosted its holdings in shares of Dyne Therapeutics by 16.0% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,153,082 shares of the company’s stock valued at $61,674,000 after buying an additional 434,977 shares during the period. Finally, Monashee Investment Management LLC acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $2,240,000. Institutional investors own 96.68% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts have recently commented on DYN shares. Morgan Stanley lowered their target price on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Royal Bank Of Canada boosted their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Finally, Sanford C. Bernstein increased their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $34.42.
Dyne Therapeutics Stock Performance
DYN opened at $26.15 on Tuesday. The business’s 50 day moving average is $23.02 and its 200-day moving average is $19.55. The stock has a market cap of $4.88 billion, a PE ratio of -7.85 and a beta of 1.07. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a twelve month low of $11.65 and a twelve month high of $27.31.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). On average, analysts predict that Dyne Therapeutics, Inc. will post -3.37 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Jason P. Rhodes sold 2,160,516 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner acquired 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $17.12 per share, for a total transaction of $42,800.00. Following the completion of the purchase, the director owned 18,000 shares of the company’s stock, valued at approximately $308,160. This represents a 16.13% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 9,000 shares of company stock valued at $156,800 and have sold 4,139,196 shares valued at $99,449,852. Insiders own 9.46% of the company’s stock.
Dyne Therapeutics Company Profile
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.
Featured Stories
- Five stocks we like better than Dyne Therapeutics
- Commodities Are Booming, But These 3 ETFs Tell Different Stories
- 3 Active ETFs Making Big Moves in August
- This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem
- Birkenstock Beats the Skeptics—But Not on EPS
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN – Free Report).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
